

2024

TTY Biopharm Company Limited

Sustainability Report





About TTY Biopharm

Supply Chain Management

Governance

Environmental

Social

Statement of Independent Assurance Opinion

About TTY Biopharm

- . Consolidated revenue was \overline{NTD} 5,893,847 million in the 2024 (7.04% CAGR for 2015-2024).
- . Complete product lines for intensive cases, vaccines, and oncology continuously.
- . The oral chemotherapy drug licensed-in from Japan for first-line treatment of advanced cholangiocarcinoma, TS-1, received early breast cancer indication in August.
- The domestically produced second-line antibiotic new drug with new efficacy and new usage which has been approved and obtained NHI price.
- . Sole distributor of anesthetic formulas. Complete full-line choices for health checks, beauty surgeries, and medical operations.
- . The "cocktail therapy" was an additional product portfolio of oncology drugs for metastatic colorectal cancer that TTY cooperated with international pharmaceutical partners.
- . Agreement on a memorandum with **5 advanced Vietnamese hospitals** to facilitate the ASEAN Medical Collaboration Project.
- . TTY provided 650,000 NHI-covered vaccines in 2024.



About TTY Biopharm

Supply Chain Management

Governance

Environmental

Social

Statement of Independent Assurance Opinion

Supply Chain Management

- . Currently holding 140 valid drug licenses.
- . More than 36 pharmaceutical items were listed in the NHI Pharmaceutical Benefits and reimbursement.
- . By the end of 2024, 3 valid invention patents were awarded.
- . By the end of 2024, 202 valid trademarks were granted.
- . The trial drug is in full conformity with International PIC/S GMP Pharmaceutical standards and Good Distribution Practices for products.



About TTY Biopharm

Supply Chain Management

Governance

Environmental

Social

Statement of Independent Assurance Opinion

Governance

- . TTY has been ranked among the top 5% of TPEx-listed companies in the 11th TWSE Corporate Governance Assessment.
- . The board comprises 2 female directors and 3 independent directors, which shows a diversified and independent governance culture.
- . 8 board meetings were convened in 2024, with an attendance rate of 98.61%.
- The average advanced training of board members reached $13.22\ hours$ in 2024.
- The Remuneration Committee convened 2 meetings in total, and all members attended these meetings in person, resulting in a 100% attendance rate.
- The Audit Committee also held 5 meetings, with all members attending these meetings in person for a 100% attendance rate.
- . In 2024, the Company did not receive any penalties for illegal incidents or violating any of the relevant laws and regulations.



About TTY Biopharm

Supply Chain Management

Governance

Environmental

Social

Statement of Independent Assurance Opinion

Environmental

- . The energy emission intensity of the Lioudu and Chungli factories were 13.2 MJ / Revenue NTD Thousand, that reached the bottom point in the past 5 years.
- . The Lioudu and Chungli factories saved 455,984.79 kWh of electricity and 225.26 tonCO_2e via 11 electricity-saving measures.
- . The chemical oxygen demand (COD) emissions and the quantity of suspended solids (SS) discharged in the water of the Lioudu and Chungli factories were lower than sewer connection standards.
- The concentrations of air pollutants emitted by the Lioudu and Chungli factories meet the standards and are better than the legal requirements.
- . The Chungli and Lioudu factories achieved 100% in weekly and monthly waste clearance contractor follow-up audits.



Social

永續報告書

About TTY Biopharm

Supply Chain Management

Governance

Environmental

Social

Statement of Independent Assurance Opinion

. 114 new employees joined in 2024, providing 523 work opportunities.

In 2024, the average salary of entry-level positions was more than 1.39 times higher than the local minimum salary.

In 2024, the average training time of each employee was $108.72\ hours$.

. Free flu vaccines were offered to 919 employees and their relatives in 2024.

The Summer Internship Program (SIP) has been held for 17 consecutive years, and we promoted to the international school recently with 2,198 enrolled as of 2024 (2,066 domestically and 132 overseas) with the total number of beneficiaries reaching 417 students.



About TTY Biopharm

Supply Chain Management

Governance

Environmental

Social

Statement of Independent **Assurance Opinion**

Statement of Independent Assurance Opinion

Sustainability Report



ISO 14064-1

查验意見書編號: 25TAFGHGA11796-1/1

溫室氣體查驗意見書

2024年溫室氣體排放資訊

台灣東洋藥品工業股份有限公司

台北市南港区園區街 3-1 號 3 樓

本公司依據 ISO 14064-3:2019 完成查驗,並符合下列標準要求

ISO 14064-1: 2018

➤ 合理保證等級:

- •賴別1:直接溫室氣體排放量:1,910.2571 公噸二氧化碳當量
- •類別2:輸入能源之間接溫室氣體排放量:8,116.4468 公噸二氧化碳當量

➤ 有限保證等級:

- ·顯別 3:運輸造成之間接溫室氣體排放量:397.7832 公噸二氧化碳當量
- ·類別 4:組織使用產品造成之間接溫室氣體排放量: 2,034.9648 公噸二氧化碳當
- ·顯別 5:與使用產品造成之間接溫室氣體排放量:79.8872 公噸二氧化碳含量
- ·顯別 6:其他來派之間接溫室氣體排放量: N.A. 公顺二氧化碳當量
- ▶ 總排放量:12,539.339 公頓二氧化碳當量





- 1.本直贴是兒書所有權證顯確详國際驗證股份有限公司·畫北市松山區南京東遊4段21號4樓之1·TEL:(02)2715-5577
- 2 表种类型需要促发器可能本分型类型www.ucscert.com.twelle

環球國際驗證股份有限公司

3.本查额意见書不可單面使用,原與查额範圍、目標、準則及結論頁面共同使用給具效力

第1页 月7页